Oxford/AZ Vaccine Hits 70% Efficacy In Phase III Trials

90% Response Seen In Half Dose Trial

 
• By Andrew McConaghie
  
Coronavirus Covid-19 Protection and Vaccine. Medical hand glove blue molding vial vaccine hypodermic needle syringe injection treatment.
The positive interim results are the third in three weeks, following on from Pfizer and Moderna.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip